Gesa  Isensee,Beat  Thürlimann,
Palbociclib and Exemestane are Active in Pretreated Low-Grade Serous Ovarian Cancer
Case Reports in Obstetrics Gynecology and Reproductive
2020
2674-5070
http://dx.doi.org/10.31487/j.CROGR.2020.03.04
https://www.sciencerepository.org/palbociclib-and-exemestane-are-active-in-pretreated-low-grade-serous_CROGR-2020-3-104 
Abstract: We describe a case of a 55-year-old woman with a rare metastatic micropapillary low-grade serous ovarian
cancer who had been heavily pretreated. A KRAS-mutation and c-MYC-amplification were detected, and
we initiated a therapy with the CDK4/6- inhibitor Palbociclib in combination with the steroidal aromatase
inhibitor exemestane. We postulated that the combination therapy leads to a blocking of the c-MYCamplification-activated cell cycle, proliferation, and inhibition of apoptosis, further enhanced by other
oncogenes like mutated RAS. This therapy showed a good and lasting response representing a new
opportunity for therapy in heavily pretreated metastatic micropapillary low-grade serous ovarian cancer.Keywords:  Low-grade serous ovarian cancer, CDK4/6-inhibitor, c-MYC amplification, RAS-mutation